-
-
-
-
-
-
-
Zenas BioPharma to present phase 3 trial results at EULAR 2026
-
-
-
-
-
-
-
Zenas BioPharma prices $300 million dual offering of notes and stock
-
-
-
-
-
-
-
Zenas BioPharma drug meets primary endpoint in multiple sclerosis trial
-
-
-
-
-
-
-
InnoCare drug meets primary goal in lupus trial for Zenas partner
-
-
-
-
-
-
-
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multip
-
-
-
-
-
-
-
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
-
-
-
-
-
-
-
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
-
1,168,812 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

